| Name | C75 |
| Description | C75 is a fatty acid synthase (FASN) inhibitor (IC50 = 35 μM in PC3 cells) with cell permeability and the ability to activate CPT1A. This compound possesses antitumor activity and is commonly used in cancer-related experimental research. |
| In vitro | Methods: The in vitro activity of C75 was validated using HeLa and CaSki cells. Cells were pretreated with 50 μM C75 for 1 hour, followed by wound healing, Transwell migration/invasion, and tube formation assays.
Results: C75 significantly inhibited the migration, invasion, and lymphangiogenesis abilities of cervical cancer cells. [1] |
| In vivo | Methods: BALB/c nude mice were used to establish a cervical cancer lymph node metastasis model, with HeLa or CaSki cells inoculated into the footpad. C75 was administered via intraperitoneal injection at a dose of 10 mg/kg every other day for 2 weeks, with vehicle as control.
Results: C75 treatment significantly suppressed popliteal lymph node volume and metastasis rate, and reduced lymphatic vessel density at the tumor site. [1]
Methods: A 4T1 breast cancer-bearing Balb/c mouse model was used, with C75 administered via intraperitoneal injection at a dose of 10 mg/kg every 3 days for 17 consecutive days.
Results: C75 monotherapy mildly inhibited tumor growth, while combination with CYH33 synergistically enhanced antitumor efficacy, increased FFA levels in tumor tissue, promoted CD8⁺ T cell infiltration, and reduced M2 macrophages. [2] |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 0.5% CMC-Na : 5 mg/mL (19.66 mM), Suspension.
DMSO : 75.6 mg/mL (297.26 mM), Sonication is recommended.
|
| Keywords | PC3 cell | FattyAcidSynthase | Fatty Acid Synthase (FASN) | Fatty Acid Synthase | C75 | C 75 |
| Inhibitors Related | 2-Octanone | Betulin | Malic enzyme inhibitor ME1 | Maltitol | Coenzyme A | Pyrazinamide | A-769662 | trans-Chalcone | Orlistat | L-Carnitine | Pseudoprotodioscin | Lycorine |
| Related Compound Libraries | Bioactive Compound Library | Anti-Obesity Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Infection Compound Library | Anti-Cancer Active Compound Library |
United States
